首页> 外文期刊>ACP Journal Club >Defibrillator therapy improved quality of life in CHF; amiodarone did not
【24h】

Defibrillator therapy improved quality of life in CHF; amiodarone did not

机译:除颤器治疗改善了瑞士法郎的生活质量;胺碘酮没有

获取原文
获取原文并翻译 | 示例
           

摘要

QuestionnnIn patients with congestive heart failure (CHF), does implantable cardioverter-defibrillator (ICD) therapy or amiodarone improve quality of life (QOL)? nnMethodsnnDesign: Randomized controlled trial (RCT) (Sudden Cardiac Death in Heart Failure Trial [SCD-HeFT]). ClinicalTrials.gov NCT00000609.nnAllocation: {Concealed}†.*nnBlinding: Blinded (patients and clinicians, for comparison of amiodarone with placebo).*nnFollow-up period: 30 months.nnSetting: Canada, United States, and New Zealand.nnPatients: 2521 patients (mean age 60 y, 77% men) who had New York Heart Association chronic, stable class II or III CHF and left ventricular (LV) ejection fraction 35%.nnIntervention: State-of-the-art medical therapy with conservatively programmed single-chamber ICD (n = 816), amiodarone (n = 830), or amiodarone placebo (n = 833).nnOutcomes: Cardiac physical functioning (Duke Activity Status Index) and psychological well-being (36-item Short-Form Mental Health Inventory 5). Secondary outcomes included QOL measured by SF-36 and Minnesota Living with HF scale (score range 0 to 105, higher scores = worse function).nnPatient follow-up: 84% at 12 months; 73% at 30 months.
机译:在患有充血性心力衰竭(CHF)的患者中,植入式心脏复律除颤器(ICD)疗法或胺碘酮是否可以改善生活质量(QOL)? nnMethodsnnDesign:随机对照试验(RCT)(心力衰竭试验中的心脏猝死[SCD-HeFT])。 ClinicalTrials.gov NCT00000609.nn分配:{隐藏}†。* nn盲:盲人(患者和临床医生,用于胺碘酮与安慰剂的比较)。*随访期:30个月。nn设置:加拿大,美国和新西兰。nn患者:2521例患者(平均年龄60岁,男性占77%),他们患有纽约心脏协会的慢性,稳定的II级或III级CHF且左心室(LV)射血分数为35%.nn干预措施:采用保守编程的单腔ICD(n = 816),胺碘酮(n = 830)或胺碘酮安慰剂(n = 833)。形成心理健康清单5)。次要结局包括通过SF-36和明尼苏达州生活指数(HF)量表(得分范围为0至105,评分较高=功能较差)进行的QOL测量。患者随访:12个月时为84%; 30个月时73%。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号